The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis

New Guideline: NSAIDs Effective in Treating Ankylosing Spondylitis & Nonradiographic Axial Spondyloarthritis

May 6, 2016 • By Richard Quinn

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Generic_Practice_Management_500x270First-of-their-kind recommendations provide U.S.-based clinicians a clear direction for treating patients with ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpA), according to a member of the working group that developed the guideline.¹

You Might Also Like
  • NSAIDs Effective for Early Axial Spondyloarthritis
  • Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
  • ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations
Also By This Author
  • Expert Q&A: Dr. Michael Lockshin on APS

The treatment recommendations, published in the February 2016 issue of Arthritis & Rheumatology, were a joint effort by the American College of Rheumatology, the Spondylitis Association of America and the Spondyloarthritis Research and Treatment Network (SPARTAN).

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The guideline affirms the role of NSAIDs as first-line treatment in active AS and of TNF inhibitors as second-line therapies in case NSAIDs fail to provide sufficient symptomatic relief,” says Joerg Ermann, MD, a rheumatologist at Brigham and Women’s Hospital in Boston, member of the SPARTAN research committee and contributor to the new recommendations. “An adequate trial of NSAIDs, according to the recommendations, is a ‘lack of response [or intolerance] to at least two different NSAIDs over one month or incomplete responses to at least two different NSAIDs over two months.’

“From a practical perspective, see the patient, make a plan to try one NSAID at full dose, and if that doesn’t work, try a second one. And if neither sufficiently relieves symptoms, then move on to a TNF inhibitor. There is no role for traditional [disease-modifying anti-rheumatic drugs] or systemic corticosteroids in treating axial symptoms in SpA.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Ermann notes that the new guideline is similar to that previously published by the European group, Assessment of SpondyloArthritis International Society (ASAS), but reflects the clinical practice of rheumatology in North America. Most notably in the new guideline, there are no threshold values for the patient’s BASDAI or ASDAS to initiate TNF inhibitor therapy.

“The guideline also confirms nr-axSpA as a disease entity,” he says. “We reviewed the literature separately. Nr-axSpA, as of today, is not an FDA-approved indication for treating patients with TNF inhibitors. However, the literature suggests that these drugs are indicated for patients with nr-axSpA.”

The working group used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methodology to assess the quality of evidence. Dr. Ermann notes the literature reviews revealed a lack of solid evidence for clinical care of patients with axial SpA.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Ermann also says IL-17A inhibitors—the new kid on the block—were not considered, adding that a recommendations “update will be needed in the near future.”


Richard Quinn is a freelance writer in New Jersey.

Reference

  1. Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Rheumatol. 2016 Feb;68(2):282–298. doi: 10.1002/art.39298. Epub 2015 Sep 24.

Pages: 1 2 | Single Page

Filed Under: Conditions, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Arthritis & Rheumatology, axial spondyloarthritis (SpA), Guidelines, Nonsteroidal anti-inflammatory drugs (NSAIDs), NSAIDs

You Might Also Like:
  • NSAIDs Effective for Early Axial Spondyloarthritis
  • Rheumatologists Make Progress Defining Spectrum of Axial Spondyloarthritis
  • ACR’s New AS & Nonradiographic Axial SpA Treatment Recommendations
  • Abaloparatide Promising for Osteoporosis; NICE Draft Guidelines Include Secukinumab for Ankylosing Spondylitis

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)